Datopotamab Deruxtecan Biologics License Application Accepted in the US for Patients With Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer

AstraZeneca and Daiichi Sankyo’s Biologics License Application for datopotamab deruxtecan has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received prior systemic therapy for unresectable or metastatic disease.